OncoMatch/Clinical Trials/NCT06145308
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Is NCT06145308 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for salivary gland carcinoma.
Treatment: Cohort 1 (HER2-positive, RC48-ADC) · Cohort 2 (NTRK-fusion or NTRK-mutant) · Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone) · TROP2 ADC · TKI · Albumin-paclitaxel + platinum · Albumin-paclitaxel + carboplatin + apatinib + camrelizumab · albumin-bound paclitaxel+trastuzumab+pyrotinib · HER2,trastuzumab deruxtecan± pertuzumab · AR,darolutamide + goserelin+pertuzumab/trastuzumab · AR,darolutamide +goserelin +docetaxel · ivonescimab + investigator-choice platinum doublet+ · iparomlimab + tuvonralimab · cadonilimab · CDK4/6 inhibitor+AI or fulvestrant · alpelisib+fulvestrant · PARP inhibitor · enfortumab vedotin · HER2, pyrotinib + pertuzumab/trastuzumab — Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and safety of precision therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Endocrine / hormonal
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) immunohistochemical staining
HER2/NTRK/AR/TROP-2 immunohistochemical staining
Required: NTRK1 immunohistochemical staining
HER2/NTRK/AR/TROP-2 immunohistochemical staining
Required: NTRK2 immunohistochemical staining
HER2/NTRK/AR/TROP-2 immunohistochemical staining
Required: NTRK3 immunohistochemical staining
HER2/NTRK/AR/TROP-2 immunohistochemical staining
Required: AR immunohistochemical staining
HER2/NTRK/AR/TROP-2 immunohistochemical staining
Required: TACSTD2 immunohistochemical staining
HER2/NTRK/AR/TROP-2 immunohistochemical staining
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06145308 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ERBB2?
Yes, ERBB2 immunohistochemical staining is a required biomarker for enrollment.
Does this trial require NTRK1?
Yes, NTRK1 immunohistochemical staining is a required biomarker for enrollment.
Does this trial require NTRK2?
Yes, NTRK2 immunohistochemical staining is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 100 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages